Lido Advisors’s Halozyme HALO Stock Holding History

Lido Advisors’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,000	Closed	-$202K	–	411
2017 Q4	$202K	Buy	+10,000	New	+$184K	0.03%	286

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lido Advisors's HALO Position: Q1 2018 in Review

Lido Advisors sold out of Halozyme (HALO) in Q1 2018, closing a stake of 10,000 shares — an estimated $202K sold.

Lido Advisors first reported a position in HALO in Q4 2017 and held it in 1 quarter. The position peaked at $202K in Q4 2017. 209 funds tracked by Wall St. Rank hold HALO as of Q1 2018.

Lido Advisors reported no remaining Halozyme position as of Q1 2018 after selling out during the quarter.
Lido Advisors sold 10,000 Halozyme shares in Q1 2018, an estimated $202K.
Lido Advisors first reported a position in Halozyme in Q4 2017 and held it in 1 quarter.
Lido Advisors's Halozyme position peaked at $202K in Q4 2017.
209 funds tracked by Wall St. Rank held Halozyme as of Q1 2018.

Based on Lido Advisors's 13F filing for Q1 2018, filed 10 May 2018.